A commentary published by Medscape on August 19, 2026 argues that Eli Lilly’s retatrutide expanded access program — the compassionate use pathway that has made headlines this summer — has become a “gatekeeper gauntlet” that risks pitting physicians against their patients (Medscape: Retatrutide: Pitting Physician Against Patient).
Written by Caroline Messer, MD, an endocrinologist and clinical associate professor at Mount Sinai School of Medicine, the piece is notable because it shifts the expanded-access debate from whether obese patients should qualify (the subject of recent PolitiFact and STAT coverage) to how the process actually works in practice — and how its design places an unusual burden on individual clinicians.
The eligibility bar is already high
By mid-2026, Messer notes, retatrutide’s Phase 3 dataset is well established: up to roughly 28–30% average weight loss at the highest doses, significant improvements in cholesterol, blood pressure, sleep apnea severity and knee osteoarthritis pain, and a safety profile broadly similar to semaglutide and tirzepatide. Lilly is expected to file for FDA approval in the first quarter of 2027.
But for patients with severe, treatment-resistant obesity and life-threatening comorbidities right now, she argues the expanded access pathway is “more of an obstacle than it is a bridge.” To be considered at all, a patient must:
- Be at least 18 years old
- Have obesity that hasn’t responded adequately despite being on the highest approved, tolerable dose of a current obesity medication
- Have at least two serious or life-threatening obesity-related health problems being actively managed by a medical team
- Be unable to enroll in an ongoing retatrutide trial
That is a high bar before a request is even submitted — and it mirrors the criteria Lilly published when it expanded its compassionate use program earlier in August (our coverage here).
Three sequential gatekeepers
Even a qualifying patient then faces three approvals that run one after another, each on its own timeline:
- Lilly’s expanded access office issues a letter of authorization referencing the drug’s investigational new drug application — described as the longest and least predictable step, with no guaranteed timeline. Week to months is possible. Lilly has not disclosed how many requests it will approve, how long treatment may continue, or who covers the cost of the drug and its monitoring.
- The physician files FDA Form 3926 with the U.S. Food and Drug Administration.
- An institutional review board (IRB) reviews the request on ethical grounds. Often expedited (24–48 hours), this step typically requires hospital affiliation or an IRB chair concurrence for unaffiliated doctors.
Because the steps run strictly in sequence, a “no” — or simply a lack of response — at any single gate stops everything. There is no appeals process, no single point of accountability, and no way to run the steps in parallel. Messer likens the result to a patient with a serious, active comorbid condition waiting, by design, on a process that “can stretch to the better part of a year before a single dose is ever authorized.”
Unusual pressure on the clinician
The commentary’s central argument is that this places disproportionate pressure on the individual physician. The doctor did not design the trial, does not set Lilly’s internal approval capacity, does not sit on the IRB, and has no leverage over any of the three gatekeepers. The result, Messer warns, can negatively impact the physician–patient relationship — a patient who trusts their doctor to get them a drug that has dominated news coverage, facing a process the doctor cannot control.
Messer is careful to say she believes in safeguards around investigational drugs. Her proposed fixes are procedural rather than deregulatory: a published timeline commitment from the manufacturer, a defined answer on cost and duration before a patient applies, and coordination between the three approval gates so they do not run in total sequence.
Canadian context
The expanded access process Messer describes is a U.S. pathway. It matters to Canadians chiefly as a contrast with the domestic analogue: Health Canada’s Special Access Programme (SAP), which permits a physician to request an unapproved drug for a specific patient with a serious or life-threatening condition when no approved alternative exists (how to get retatrutide in Canada).
Canadian SAP requests are submitted directly to Health Canada by the treating physician and are reviewed case by case — a single regulatory gate rather than the three sequential U.S. gates Messer describes. Historically, Health Canada has used SAP far more restrictively than U.S. expanded access, typically for immediately life-threatening conditions, which makes experimental weight-loss access even harder to obtain in Canada.
For Canadians, the practical takeaways from Messer’s commentary are unchanged:
- Expanded access is not a realistic path for most patients, in either country — the eligibility bar, the opaque timelines, and the cost uncertainty all stand in the way.
- Clinical trial enrollment at a Canadian site remains the most realistic route to retatrutide, supplying the drug under medical supervision at no cost to the patient.
- Nothing sold online is the real drug. No legitimate compassionate use, expanded access, or “research” retatrutide is available for purchase anywhere, and Health Canada and regulators on both sides of the border have warned against unapproved products (black market warnings).
Sources
- Medscape: “Retatrutide: Pitting Physician Against Patient” — Caroline Messer, MD (August 19, 2026)
- STAT: Eli Lilly to allow more patients to apply for special access to unapproved obesity drug (August 3, 2026)
- FDA: Expanded Access
- FDA: Form FDA 3926 — Individual Patient Expanded Access
- Health Canada: Special Access Programme
Disclaimer: GetRetatrutide.ca is an independent educational resource. This article does not constitute medical advice. Retatrutide is not approved by Health Canada or the FDA.